Poseltinib (HM71224, LY3337641) shows a highly selective inhibition for Bruton’s tyrosine kinase (BTK) with IC50 of 1.95 nM, in which the selectivity toward other BMX, TEC and TXK are 0.3, 2.3 and 2.4 fold, respectively.
[1] Kim YY, et al. Arthritis Res Ther. 2017 Sep 26;19(1):211.
















